Eli Lilly Projected to Reach $2 Trillion Valuation by 2031

Eli Lilly Targets $2 Trillion Valuation by 2031

Although its performance has cooled since that milestone amid valuation questions, the pharmaceutical giant is riding a powerful tailwind that could propel its valuation to $2 trillion over the next five years. That projection would nearly double the company’s current market capitalization.

Over the past three years, Eli Lilly’s revenue growth has mirrored a smaller tech corporation rather than a major pharmaceutical company. While top-line growth rates are expected to decline as new competition enters the market, the company’s revenue expansion is projected to remain well above the typical average for pharmaceutical giants. Drugmakers of this size typically view high-teens revenue growth as very strong, and Eli Lilly is expected to stay comfortably above that threshold.

Tirzepatide Dominates the GLP-1 Market Opportunity

The lion’s share of Eli Lilly’s revenue stems from the fast-growing GLP-1 market, anchored by its flagship compound tirzepatide. Marketed as Mounjaro for diabetes and Zepbound for weight loss, tirzepatide is currently the world’s best-selling compound despite having been on the market for just about four years.

Some analysts estimate tirzepatide could reach $62 billion in annual sales by 2030, which would represent the highest peak ever recorded in the pharmaceutical industry. To sustain this momentum against incoming competition and pressure on pricing power, Eli Lilly is pursuing strategic medium-term label expansions. One of the most promising indications targets metabolic dysfunction-associated steatotic liver disease, a condition affecting millions of patients with a high unmet medical need that could add billions in peak annual revenue.

Novo Nordisk Sues Eli Lilly for False Advertising Over Weight-Loss Drugs

Expanding Portfolios and Artificial Intelligence Investments

Beyond its established blockbuster, Eli Lilly launched Foundayo earlier this year. Foundayo is an oral GLP-1 currently approved for weight loss—where it is performing well and attracting mostly new patients—with potential future approvals across diabetes, obstructive sleep apnea, and hypertension. Meanwhile, the company’s clinical pipeline features retatrutide, a phase 3 asset demonstrating weight-loss efficacy numbers that rival bariatric procedures.

Diversification extends outside the GLP-1 market through recent approvals including Kisunla for Alzheimer’s disease and Omvoh for ulcerative colitis, each projected to eventually generate over $1 billion in annual sales. Acquisitions have further expanded the pipeline across multiple therapeutic areas. In addition to new drug launches, Eli Lilly is investing in artificial intelligence to drive productivity gains, aiming to reduce expenses associated with discovering and developing medicines to bolster earnings and profit margins.

Evaluating Valuation and Growth Potential

Valuation remains a central point of discussion for investors evaluating the stock. Eli Lilly currently trades at 34x forward earnings, a multiple that appears elevated when compared to the broader industry average of 18. However, proponents argue that the pricing remains reasonable relative to the company’s extraordinary growth potential, expanding product portfolio, and technological investments heading toward 2031.